"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >
"We are very excited about RNN; it's an early-stage oncology company with multiple shots on goal." (7/31/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Christopher James More >
The Life Sciences Report Biotech Watchlist Portfolio Tracker
It has been a boom year for biotechs, and most of the companies on The Life Sciences Report's Biotech Watchlist 2013 have risen with the proverbial tide. The Watchlist companies were selected by industry experts based on a variety of factors, including sound science, good management, therapy area and catalysts keyed to the drug development process. We have been tracking the companies throughout the year: With our new Portfolio Tracker, it is now easy for Life Science Report readers to do the same.
October 2013 Biotech Watchlist Update
January 2013 Biotech Watchlist
April 2013 Biotech Watchlist Update
How Are They Doing? Update on the Progress of Expert Picks
The Approval Process in Action (infographic)
The chart below shows stock prices for the 17 companies on the 2013 Biotech Watchlist. The heavy green line shows the average gain/loss of the portfolio as a whole. Portfolio average change year-to-date is [loading].
About These Individual Charts
The Yahoo finance charts provided below are updated in real time and show stock prices for each company for the year to date. Time spans for catalysts identified by Biotech Watchlist analysts are lighted in green.
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >